Brazilian health regulator Anvisa on Monday said it had dropped a clinical study for the Covaxin vaccine for COVID-19 developed by India’s Bharat Biotech, in the midst of claims of irregularities in the government’s efforts to purchase a great many dosages of the shot.
Bharat on Friday said it had ended a notice of understanding with the nearby partner organization going about as its intermediary in Brazil, with Anvisa saying on Monday that the trials couldn’t go ahead as a result and would be dropped.
Anvisa had previously suspended the trials briefly.
Brazil’s health regulator had before suspended Covaxin’s crisis use application, recorded by an intermediary following up for the COVID-19 vaccine developed by India’s Bharat Biotech.
Anvisa said the intermediary, Precisa, didn’t submit, or only partially submitted, mandatory and fundamental archives for the vaccine. The shot has gotten exceptionally controversial in Brazil over charges of irregularities in the government’s efforts to purchase 20 million portions.